Slides
Page 1
1 Vitrafy Life Sciences Limited (ASX: VFY) ACN 622 720 254 vitrafy.com Strictly Private & Confidential IMV Strategic Partnership 15 January 2026 For personal use only
Page 2
2 Overview Vitrafy has entered into a strategic, commercial agreement to work with global leader, IMV, on animal reproduction cryopreservation Strategic Commercial Agreement With global, animal reproduction leader, IMV Technologies (“IMV”). Product Alignment Accelerated access to the animal market at scale, for Vitrafy’s entire product suite via a trusted parter. Growth Catalyst Partnership to integrate Vitrafy’s cryopreservation technology with IMV’s global product suite. Revenue Generative Vitrafy will receive up to A$480k in monthly fees over the 12-month term, plus milestone payments of up to A$450k. Partnering with the market leader in a highly concentrated animal reproduction market. In line with Vitrafy’s strategy to scale the animal reproduction market. Enabling Vitratfy to focus directly on the human health market in the USA. Market Leading Partner Strategy Execution For personal use only
Page 3
3 Introduction to IMV IMV is the market leader in animal reproduction market. Established Market Leader • Founded in 1963 • Experts in artificial insemination, semen preservation, and reproductive diagnostics • Proven commercialisation track record Trusted Partner • Involved in half a billion artificial insemination processes each year • Global footprint with significant market share across multiple species • Conglomerate operating across 4 continents and a presence in 128 countries Growth Focused • Culture of product leadership in market • Disciplined, growth-focused commercial execution • Revenue growth opportunities across large existing customer base For personal use only
Page 4
4 The Agreement Combining Vitrafy’s next-generation cryopreservation technology with IMV’s globally recognised platform to set a new industry benchmark. • Exclusive, 12-month strategic collaboration to co-develop a solution that brings the strengths of both organisations - expertise, product portfolios and scientific innovation. • Pathway to a long-term, commercial agreement between IMV and Vitrafy. • During the 12-month term, Vitrafy and IMV will undertake: • development and validation testing across aquaculture, bovine and porcine • integration of the two product suites • detailed commercial analysis to take the product to market • Vitrafy will receive a recurring monthly fee for the provision of its cryopreservation technology, totalling up to ~A$480k over the 12-month term. Further payments for the successful achievement of pre-determined milestones of up to ~A$450K. • The Agreement may be extended for a further 6 months. For personal use only
Page 5
5 In summary • Validates the use of Vitrafy’s technology in a commercial setting • Leverages IMV’s significant expertise in this market • Provides access to a significant share of the animal reproduction market • Allows Vitrafy to focus on the high growth human health market in the US For personal use only
Page 6
6 Q&A For personal use only